CG Asset Management LLC reduced its position in Amgen Inc. (NASDAQ:AMGN) by 29.7% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,683 shares of the medical research company’s stock after selling 3,250 shares during the period. CG Asset Management LLC’s holdings in Amgen were worth $1,169,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in the company. Oakworth Capital Inc. boosted its stake in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares in the last quarter. Delta Asset Management LLC TN boosted its position in Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock valued at $155,000 after buying an additional 85 shares in the last quarter. Capital Advisors Ltd. LLC boosted its position in Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock valued at $164,000 after buying an additional 6 shares in the last quarter. Vigilant Capital Management LLC boosted its position in Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock valued at $195,000 after buying an additional 33 shares in the last quarter. Finally, Calamos Wealth Management LLC acquired a new position in Amgen during the second quarter valued at $202,000. 79.15% of the stock is owned by institutional investors.
Amgen Inc. (NASDAQ:AMGN) traded down 0.29% on Wednesday, hitting $163.85. The stock had a trading volume of 1,932,956 shares. Amgen Inc. has a 1-year low of $139.02 and a 1-year high of $176.85. The firm has a market capitalization of $122.62 billion, a price-to-earnings ratio of 16.77 and a beta of 0.94. The company’s 50 day moving average is $170.32 and its 200-day moving average is $162.15.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The company earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. During the same period in the previous year, the business earned $2.57 earnings per share. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. On average, analysts forecast that Amgen Inc. will post $11.35 EPS for the current year.
Several equities analysts recently weighed in on AMGN shares. BMO Capital Markets reissued a “buy” rating and set a $186.00 price objective on shares of Amgen in a research report on Tuesday, July 12th. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $165.78 price objective for the company in a research report on Wednesday, July 27th. Leerink Swann reissued a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a research report on Monday, August 1st. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and set a $206.00 price objective (up previously from $204.00) on shares of Amgen in a research report on Tuesday, September 27th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $184.94.
In other news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.20% of the stock is currently owned by insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.